Abeona Therapeutics: Despite Some Competitive Pressure, This Looks Undervalued

Group 1 - Abeona Therapeutics Inc. (NASDAQ: ABEO) has a lead program called pz-cel (prademagene zamikeracel), which is an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa [1] - The company has not been reviewed in detail for approximately six years, indicating a potential gap in investor awareness or interest [1] Group 2 - The Total Pharma Tracker offers tools for DIY investors, including a software that provides extensive curated research material for any ticker [1] - In-house experts are available to assist investors by identifying the best investable stocks along with buy/sell strategies and alerts [2]